COMMENTARY

Coronary Artery Calcium Scoring Can Help Guide Statin Therapy

Matthew J. Budoff, MD

| Disclosures | January 14, 2016
 

Several cardiologists have questioned whether assessment of coronary artery calcium (CAC) should be used to evaluate patients for statin therapy, as currently recommended in guidelines since the National Cholesterol Education Program (NCEP) Adult Treatment Panel III update was published in 2004.[1] Serum biomarkers and imaging tests are used to target higher- and lower-risk patients in whom statins might produce a larger or smaller absolute event reduction.

CAC Is Guideline Recommended

Risk stratification with CAC is more robust than previously published data with C-reactive protein (CRP) or other biomarkers, and is a class IIa recommendation in the 2010 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Task Force Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults.[2] These guidelines refer to a noncontrast, limited chest CT scan acquired with an approximate 3- to 5-second breath hold. The 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk states that "assessing CAC is likely to be the most useful of the current approaches to improving risk assessment among individuals found to be at intermediate risk after formal risk assessment."[3]

Disease Burden vs Risk Factor

Because CAC measurement allows for integration of the exposure to risk factors over a lifetime, CAC is best considered a measure of disease burden rather than a risk factor. This explains why it is such a powerful predictor of risk and is such a valuable negative predictor when the CAC score is 0. Influential cardiovascular epidemiologist Sir Geoffrey Rose (1926-1993) stated, "The best predictor of a life-threatening illness is the early manifestation of a life-threatening illness."[4] Clearly this applies to CAC scanning, where finding atherosclerosis represents an opportune time to intervene with lifestyle changes, statins, aspirin, and potentially even angiotensin-converting enzyme (ACE) inhibitors. CAC testing has been validated in multiple studies, including Dallas Heart,[5] Rotterdam,[6] St Francis Heart,[7] Multi-Ethnic Study of Atherosclerosis (MESA),[8] and others. CAC has been shown to be the best predictor of future events, in the general population, the elderly,[9] and in persons with diabetes.[10] It provides more robust risk prediction than carotid intima media thickness, CRP, ankle-brachial index, and family history of premature heart disease.[11]

CAC has been shown to better stratify those patients in MESA who would benefit from statins,[12] aspirin,[13] ACE inhibitors,[14] and the polypill[15] versus other biomarkers. All of these studies demonstrate that CAC is the most useful test we have for identifying those with early atherosclerosis, but more important, it may be an even more powerful determinant that patients don't need therapy (Power of Zero). The absence of atherosclerosis in a given patient would potentially obviate the need for anti-atherosclerotic therapies (such as aspirin, statin, and ACE inhibitors). A recent study demonstrated that a CAC score of 0 confers a 15-year warranty period against mortality in individuals at low to intermediate risk, unaffected by age or sex.[16]

Is CAC Cost-Effective?

Many preventive physicians find direct measurement of the disease and integration of cumulative risk factor exposure very appealing. Imagine the cost savings if we were to apply CAC scoring to a study like the JUPITER trial, where statins prevented events but required a high number needed to treat (NNT). Blaha and colleagues[17] observed a population in MESA that met inclusion criteria for JUPITER for a median follow-up of 5.8 years (IQR 5.7–5.9). Almost half of the patients in the MESA JUPITER population had CAC scores of 0, and in this group, rates of coronary heart disease (CHD) events were 0.8 per 1000 person-years (ie, < 0.1%). Nearly three quarters of all coronary events were in the 25% of participants with CAC scores higher than 100 (20.2 per 1000 person-years or 2% per year).

To prevent one CHD event, the predicted 5-year NNT with a statin was 549 for a CAC score of 0, 94 for scores of 1–100, and 24 for scores above 100. By comparison, high-sensitivity CRP was not associated with CHD or cardiovascular events after multivariable adjustment.

Thus, CAC demonstrated that 50% of the population who meet criteria for statins but have no measurable atherosclerosis would likely not benefit. Studies have shown that using CAC testing is more cost-effective[18,19] than the current widespread statin use that is advocated by the ACC/AHA pooled cohorts. Treating all is rarely cost-effective, and patients are less likely to want to stay on therapy if they do not perceive personal benefit. Visualizing coronary calcium is associated with improvements in adherence to statin therapy.[20] Thus, not only can CAC identify who would benefit from anti-atherosclerotic therapies, but it also helps identify those who may not need treatment, and improves compliance when patients are then instructed to take these therapies.

Treating According to Calcium Score

What should you do differently when presented with different scores/findings? It is important to understand that a zero score portends a very low risk, and typically lifestyle changes alone will suffice; the NNT with statins to reduce a heart attack in individuals with zero calcium is > 500. Treating 500 persons to reduce one event is neither practical nor cost-effective. Side effects from statins, such as myalgias,[21,22] occur at a rate greater than 1 per 500, so the risk-benefit ratio of statins in a person with a zero score is either harmful or neutral and is not beneficial. Remember, CAC testing is not generally recommended in persons younger than 40 years.[3] CAC scores of either > 75th percentile for age and gender or ≥ 300 (Agatston units) are deemed high risk per the 2013 cholesterol guidelines[23] and warrant high-dose statins. In the St Francis Heart randomized study, atorvastatin reduced cardiovascular events by 42% in those with scores > 400, with an NNT to reduce one myocardial infarction or death of only 17.[24]

On the basis of current guidelines from both NCEP and ACC/AHA:

  • CAC scores < 75th percentile and < 300 are to be treated with low- to moderate-dose statins.

  • CAC scores > 75th percentile or ≥ 300 are to be treated with high-dose statins.

  • CAC score of zero should be considered for lifestyle modification, unless a compelling indication for statin already exists.

As for aspirin, in the MESA study, individuals with CAC scores ≥ 100 had an estimated net benefit from aspirin regardless of their traditional risk status (NNT = 92; estimated 5-year number needed to harm [NNH] = 442 for a major bleed).[13] Conversely, individuals with a score of zero were unlikely to benefit (5-year NNT = 2036 for individuals with a Framingham risk score [FRS] < 10% and 808 for FRS ≥10%; 5-year NNH = 442 for a major bleed). This was true for men and women and regardless of age. Similar data exist for ACE inhibitors and polypill therapies.

Treatment algorithms should be based on the results of CAC. You wouldn't put someone on chemotherapy if they didn't have cancer; similarly, we shouldn't use statins in people without atherosclerosis.

 
Latest in Cardiology

References

  1. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239. Abstract

  2. Members WC, Greenland P, Alpert JS, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:2748-2764. Abstract

  3. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-73. Abstract

  4. Rose G KK, Marmot M. Rose's Strategy of Preventive Medicine Oxford University Press; 2008.

  5. Paixao ARM, Berry JD, Neeland IJ, et al. Coronary artery calcification and family history of myocardial infarction in the Dallas Heart Study. JACC Cardiovasc Imag. 2014;7:679-686.

  6. Leening MJ, Elias-Smale SE, Kavousi M, et al. Coronary calcification and the risk of heart failure in the elderly: the Rotterdam Study. JACC Cardiovasc Imaging. 2012;5:874-880. Abstract

  7. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, c-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Col Cardiol. 2005;46:158-165.

  8. Budoff MJ, Nasir K, McClelland RL, et al. Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Col Cardiol. 2009;53:345-352.

  9. Nakanishi R, Li D, Blaha MJ, et al. All-cause mortality by age and gender based on coronary artery calcium scores. Eur Heart J Cardiovasc Imaging. 2015 Dec 24. [Epub ahead of print]

  10. Kiramijyan S, Ahmadi N, Isma'eel H, et al. Impact of coronary artery calcium progression and statin therapy on clinical outcome in subjects with and without diabetes mellitus. Am J Cardiol. 2013;111:356-361. Abstract

  11. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788-795. Abstract

  12. Martin SS, Blaha MJ, Blankstein R, et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014;129:77-86. Abstract

  13. Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7:453-460. Abstract

  14. Darabian S, Luo Y, Homat A, et al. CAC score as a possible criterion for administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers: the MultiEthnic Study of Atherosclerosis. Coron Artery Dis. 2015;26:678-685.

  15. Bittencourt MS, Blaha MJ, Blankstein R, et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63:434-443. Abstract

  16. Valenti V, B OH, Heo R, et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9,715 individuals. JACC Cardiovasc Imaging. 2015;8:900-909. Abstract

  17. Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378:684-692. Abstract

  18. Roberts ET, Horne A, Martin SS, et al. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2015;10:e0116377.

  19. van Kempen BJH, Spronk S, Koller MT, et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J Am Coll Cardiol. 2011;58:1690-1701. Abstract

  20. Kalia NK, Cespedes L, Youssef G, Li D, Budoff MJ. Motivational effects of coronary artery calcium scores on statin adherence and weight loss. Coron Artery Dis. 2015;26:225-230. Abstract

  21. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58-71. Abstract

  22. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690. Abstract

  23. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45. Abstract

  24. Kim J, McEvoy JW, Nasir K, et al. Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis Heart Trials. Circ Cardiovasc Qual Outcomes. 2014;7:315-322. Abstract

Authors and Disclosures

Author(s)

Matthew J. Budoff, MD

Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California; Program Director and Director of Cardiac CT, Division of Cardiology, Harbor-UCLA Medical Center, Torrance, California

Disclosure: Matthew J. Budoff, MD, has disclosed the following relevant financial relationships:
Received research grant from: General Electric

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....